Current pharmacological approaches and potential future therapies for Celiac disease
Authors:
- 1 October 2021
- journal article
- research article
- Published by Elsevier in European Journal of Pharmacology
- Vol. 909, 174434
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Glutenase ALV003 Attenuates Gluten-Induced Mucosal Injury in Patients With Celiac DiseaseGastroenterology, 2014
- Celiac DiseaseNew England Journal of Medicine, 2012
- Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: a randomised placebo‐controlled studyAlimentary Pharmacology & Therapeutics, 2012
- A Randomized, Double-Blind Study of Larazotide Acetate to Prevent the Activation of Celiac Disease During Gluten ChallengeAmerican Journal of Gastroenterology, 2012
- Review article: coeliac disease, new approaches to therapyAlimentary Pharmacology & Therapeutics, 2012
- Safety, Tolerability, and Activity of ALV003: Results from Two Phase 1 Single, Escalating-Dose Clinical TrialsDigestive Diseases and Sciences, 2011
- The effects of ALV003 pre-digestion of gluten on immune response and symptoms in celiac disease in vivoClinical Immunology, 2010
- Antibody-mediated blockade of IL-15 reverses the autoimmune intestinal damage in transgenic mice that overexpress IL-15 in enterocytesProceedings of the National Academy of Sciences, 2009
- The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT‐1001 in coeliac disease subjects: a proof of concept studyAlimentary Pharmacology & Therapeutics, 2007
- Celiac diet: Its impact on quality of lifeJournal of the American Dietetic Association, 2003